MARIETTA, Ga., June 3, 2019 /PRNewswire/ — MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company“), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission (“SEC“) in connection with its upcoming 2018 annual meeting of shareholders (“Annual …